AI is accelerating the next wave of life sciences research. HPE and NVIDIA are unleashing the future of genomics today with a robust AI platform that will transform what we know about the human genome, disease, and personalized medicine. Here, Mark Heuser, who leads the global partner ecosystem development for data center in healthcare and life sciences at NVIDIA, joins HPE's Rich Bird for an in-depth look at how we're accelerating genomics.
Artificial intelligence (AI) and accelerated computing are transforming healthcare and life science research. Life science organizations need greater intelligence and precision to execute their most complex workloads. Genomics utilizes vast
Many organizations are feeling the pressure as biomedical data continues to skyrocket and the limitations of legacy infrastructure challenge them to evolve. With over two million genomes to be sequenced by 2025, data volumes are expected to reach one zettabyte. The overwhelming need for analysis as well as the continued transition to more precision care makes genomics one of the most important data domains.
The genomics workflow is a complex series of data and process-intensive steps that hinge on scalable infrastructure. Choosing the right solutions is essential to optimize each phase of the workflow—from genome sequencing, raw reads, and data preprocessing to variant discovery and analysis. The entire cycle requires vast amounts of compute power to run more efficiently, speed up decision-making, and unlock the full value of data.
Applying GPU-accelerated tools across the genomics workflow allows researchers to not only pinpoint genes that might develop into medical conditions, but it also enables caregivers to improve clinical outcomes through specific tests and targeted drugs and therapies. These insights can be applied to evidence-based treatments, disease prediction and prevention, and bringing personalized medicine into widespread use.
Top life sciences organizations have unleashed the power of GPU acceleration to manage growing datasets with increased speed and accuracy:
- Providing timely access to data to multiple teams at one time
- Leveraging high-throughput virtual sequencing to evaluate billions of molecules
- Accelerating primary, secondary, and tertiary analysis of genomic data
- Scaling seamlessly as sequencer capacity increases
Next-generation sequencing (NGS) is fueling progress in genomic medicine. Due to the rapid growth of sequencing workloads, organizations are using innovative AI tools to meet the increasing demand for NGS insights. The integration of these capabilities drives remarkable improvements in genomic research to uncover the relationship between genotypes. Now, research centers around the globe are modeling the human genome against infectious diseases to promote translational medicine and personalized medicine. Academic institutions are analyzing petabytes of biomedical data to pinpoint the differences in people’s genes, environments, and lifestyles to aid in disease prevention. In pharmaceutical and biotech, companies are using AI to accelerate drug and vaccine discovery, molecular modeling, and genomic medicine to treat countless illnesses and conditions.
In the future, advancements in AI will be able to simulate the functioning of the human cell down to the subatomic level. This will let organizations observe how different biological compounds work in the human body, which dramatically reduce the time and cost required to identify drugs and treatments for clinical trials.
How HPE and NVIDIA are working together
In a joint effort, HPE and NVIDIA are supporting support the future of genomics with better insight, maximum productivity, and faster time to value. We offer a combination of industry-leading technologies that will redefine the possibilities of life sciences and help organizations pursue genomics innovation at any scale.
Our robust platform is designed to deliver accelerated compute without limits.
The platform is built on industry-leading HPE systems that are NVIDIA-Certified and GPU-enabled to accelerate any workflow. The platform features turnkey, enterprise grade NVIDIA Clara Discovery for in silico computational tools for drug development and NVIDIA Clara Parabricks for accelerated genomic analysis of panels, exomes and genomes. Clara Parabricks demonstrates 60x accelerations for state-of-the-art bioinformatics tools compared to CPU-based environments. Whole genomes can be analyzed in 22 minutes and whole exomes in just four minutes.
HPE delivers these solutions on-premises, hybrid, or with GreenLake cloud services to help simplify system and data management, reduce costs and complexity, and scale to deliver excellent performance. Organizations can choose from an extensive selection of HPE systems that are engineered for AI and powered by NVIDIA GPUs to harness unparalleled processing at any scale.
To optimize workflows for AI model development, deployment, and maintenance for accelerated workflows in healthcare, life sciences and drug discovery, customers can leverage the NVIDIA AI Enterprise software suite, which runs on HPE systems that are NVIDIA-Certified. An end-to-end, cloud-native suite of AI and data science tools, NVIDIA AI Enterprise runs on VMware vSphere and includes key enabling technologies and software for rapid deployment, management, and scaling of AI workloads in the modern hybrid cloud on virtual machines and with Kubernetes containers.
HPE provides flexible deployment options, so organizations can choose how they consume these game-changing solutions. HPE Pointnext services offer a wide range of professional, technical, and advisory support for genomics. Our experts help you create a roadmap to AI that makes it easy to transform, allowing you to focus on accelerating the performance and impact of NGS.
HPE GreenLake edge-to-cloud platform gives organizations choice in how they utilize AI. It provides the agility and scalability of the cloud with the security, simplicity, and control of on-premises IT. The HPE cloud service business and delivery model is designed to support AI and speed time to discovery in any environment, delivering technologies and resources how and when they are needed the most.
Accelerating breakthroughs in genomics
AI and GPU-acceleration are empowering the life sciences industry to supercharge computational drug development and genomics workflows. By replacing legacy infrastructure with the latest AI technologies, organizations can manage petabytes of data, ramp up research, and achieve faster results with a lower cost of ownership.
As organizations explore the possibilities of AI, they will need trusted partners with deep life sciences expertise. HPE and NVIDIA are revolutionizing life sciences operations in the most demanding research and production environments in the world. Our AI platform provides the right tools to drive value. Organizations have seen 76X improvements in throughput performance for whole genome sequencing as well as a dramatic 82X acceleration across the entire cycle.
Together, HPE and NVIDIA can help you pioneer a new age of genomics research. Let us help you see how AI solutions can accelerate the next generation of drug discovery.
Meet our Tech Insights guest blogger, Mark Heuser, NVIDIA
Insights Experts
Hewlett Packard Enterprise
twitter.com/HPE_AI
linkedin.com/showcase/hpe-ai/
hpe.com/us/en/solutions/artificial-intelligence.html
Rich_Bird
Rich Bird has worked in the IT industry for 20 years with some of the largest commercial brands. For the last 5 years he’s been focused on healthcare IT at Hewlett Packard Enterprise, and believes deeply that digital technologies can, will and need to have an impact on the delivery of better healthcare, for people all over the world. Educated in Computer Science at Coventry University, and starting his career as a network engineer for Rolls Royce, he moved into human communications roles in 2006. Rich leads teams in delivering integrated marketing campaigns into National, local and regional Governments in the UK, where Rich found his passion for making the complex concepts of IT, simple and understandable for his audience. During this time he found his true calling, Healthcare, and how digitization can improve real people lives. He created a companywide growth board focusing on the UK NHS, pulling together disparate teams of sales, marketing, solutions architects, chief technologists and the country leadership teams for HP/HPE UK. Rich is a strategic thinker who understands the practical elements that are required to get the job done and deliver real impact. His areas of specialization include Healthcare IT, Marketing, Communications, and NLP.